These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 16207107)

  • 1. Challenge and rechallenge: drotrecogin alfa (activated)-induced prolongation of activated partial thromboplastin time in a patient with severe sepsis.
    Castelli EE; Culley CM; Fink MP
    Pharmacotherapy; 2005 Aug; 25(8):1147-50. PubMed ID: 16207107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis.
    McCoy C
    Expert Opin Drug Saf; 2004 Nov; 3(6):625-37. PubMed ID: 15500421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.
    Barton P; Kalil AC; Nadel S; Goldstein B; Okhuysen-Cawley R; Brilli RJ; Takano JS; Martin LD; Quint P; Yeh TS; Dalton HJ; Gessouron MR; Brown KE; Betts H; Levin M; Macias WL; Small DS; Wyss VL; Bates BM; Utterback BG; Giroir BP
    Pediatrics; 2004 Jan; 113(1 Pt 1):7-17. PubMed ID: 14702440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical response to unintentionally rapid infusion of drotrecogin alfa (activated).
    Urban TM; Mitchell GA; Wellborn-Kim JJ; Terneus WF; Callahan CM; Mendes J; Webber SL
    Am J Health Syst Pharm; 2010 Jul; 67(14):1174-7. PubMed ID: 20592322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis.
    Macias WL; Dhainaut JF; Yan SC; Helterbrand JD; Seger M; Johnson G; Small DS
    Clin Pharmacol Ther; 2002 Oct; 72(4):391-402. PubMed ID: 12386641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice.
    Ridley S; Lwin A; Wyncoll D; Lippett S; Watson D; Gunning K; Higgins D
    Eur J Anaesthesiol; 2008 Mar; 25(3):211-6. PubMed ID: 18031590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.
    De Backer D
    Drug Saf; 2007; 30(11):995-1010. PubMed ID: 17973539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.
    Ely EW; Laterre PF; Angus DC; Helterbrand JD; Levy H; Dhainaut JF; Vincent JL; Macias WL; Bernard GR;
    Crit Care Med; 2003 Jan; 31(1):12-9. PubMed ID: 12544987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarker response to drotrecogin alfa (activated) in children with severe sepsis: results from the RESOLVE clinical trial*.
    Dalton HJ; Carcillo JA; Woodward DB; Short MA; Williams MD
    Pediatr Crit Care Med; 2012 Nov; 13(6):639-45. PubMed ID: 22791090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Static and dynamic assessment of biomarkers in surgical patients with severe sepsis.
    Lowry SF; Awad S; Ford H; Cheadle W; Williams MD; Qualy RL; McCollam JS; Bates BM; Fry DE;
    Surg Infect (Larchmt); 2004; 5(3):261-8. PubMed ID: 15684797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis.
    Bernard GR; Macias WL; Joyce DE; Williams MD; Bailey J; Vincent JL
    Crit Care; 2003 Apr; 7(2):155-63. PubMed ID: 12720562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.
    Bernard GR; Margolis BD; Shanies HM; Ely EW; Wheeler AP; Levy H; Wong K; Wright TJ;
    Chest; 2004 Jun; 125(6):2206-16. PubMed ID: 15189943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Readministration of drotrecogin alfa (activated) in an adult with severe sepsis.
    Scipione MR; Nogid B; Davanos E; DiGregorio RV
    Am J Health Syst Pharm; 2011 Sep; 68(18):1711-5. PubMed ID: 21880886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
    Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drotrecogin alfa (activated) in an infant with gram-negative septic shock.
    Sajan I; Da-Silva SS; Dellinger RP
    J Intensive Care Med; 2004; 19(1):51-5. PubMed ID: 15035755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of recombinant human activated protein C for severe sepsis.
    Bernard GR; Vincent JL; Laterre PF; LaRosa SP; Dhainaut JF; Lopez-Rodriguez A; Steingrub JS; Garber GE; Helterbrand JD; Ely EW; Fisher CJ;
    N Engl J Med; 2001 Mar; 344(10):699-709. PubMed ID: 11236773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated).
    Micek ST; Isakow W; Shannon W; Kollef MH
    Pharmacotherapy; 2005 Jan; 25(1):26-34. PubMed ID: 15767217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment.
    Vincent JL; Bernard GR; Beale R; Doig C; Putensen C; Dhainaut JF; Artigas A; Fumagalli R; Macias W; Wright T; Wong K; Sundin DP; Turlo MA; Janes J
    Crit Care Med; 2005 Oct; 33(10):2266-77. PubMed ID: 16215381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
    Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; McL Booth FV
    Surgery; 2006 Nov; 140(5):726-39. PubMed ID: 17084715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of drotrecogin alfa (activated) in surgical patients with severe sepsis.
    Fry DE; Beilman G; Johnson S; Williams MD; Rodman G; Booth FV; Bates BM; McCollam JS; Lowry SF;
    Surg Infect (Larchmt); 2004; 5(3):253-9. PubMed ID: 15684796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.